Home Contact Sitemap

PedAM

Pediatric Disease Annotations & Medicines




Disease neutropenia
Symptom C0015967|fever
Sentences 61
PubMedID- 23228190 Dose limiting toxicity (dlt) was defined as grade 3 neutropenia with fever or infection; grade 4 neutropenia persisting ≥ 7 days; grade 3 thrombocytopenia with bleeding or grade 4 thrombocytopenia > 7 days; any non-hematological toxicity grade 3 or 4 except alopecia, nausea and vomiting; increase in urinary retention parameters ≥ grade 2; peripheral sensory neuropathy ≥ grade 3. relation between study drug and toxicity was evaluated with respect to the differences of the side effects of fluoruracil/leucovorin and capecitabine.
PubMedID- 23943780 neutropenia in patients with shanghai fever was probably induced by p aeruginosa infection rather than a predisposing factor for the infection.
PubMedID- 25444524 Study design: episodes of fever without neutropenia (absolute neutrophil count anc >/=500 cells/mm(3)) were reviewed retrospectively in pediatric oncology patients with a cvc undergoing chemotherapy.
PubMedID- 25345994 fever and fever with neutropenia (fn) were the two most common diagnoses, accounting for almost 20% of visits.
PubMedID- 24455636 Background: neutropenia with fever is a common syndrome in patients with hematologic malignancies who have a high risk of infectious diseases.
PubMedID- 23476759 A total of 412 citations were identified for two cancer-treatment-related symptoms of diarrhea and fever with neutropenia (see figure 1).
PubMedID- 25671574 Virtually applying different tldfs, the number of episodes of fever (with or without neutropenia) increased from 124 at limitstandard to 291 (235%) at 38.5°c, to 604 (487%) at 38.0°c, and to 1191 (960%) at 37.5°c.
PubMedID- 25409861 neutropenia with or without fever is a relevant cause of morbidity, mortality and costs, compromising treatment administration and clinical outcomes.
PubMedID- 21747881 neutropenia with fever and uncontrolled severe infection were complications in 87% and 27% of the patients, respectively.
PubMedID- 22588015 One such life-threatening complication in immunocompromised children remains infection, which frequently manifests as the occurrence of fever with neutropenia 4.
PubMedID- 23560388 Approximately 60% of episodes of fever in patients with neutropenia are frequently correlated with documented bloodstream infection (bsi).
PubMedID- 23088794 The overall favorable response rate (rr) was 64.8% when the resolution of fever during neutropenia was included in the response criteria and 84.5% when excluded.
PubMedID- 26185609 Secondly, around 70% of fevers in neutropenia are classified as fever of unknown origin (fuo)92 in which antibiotic therapy could be unneeded.
PubMedID- 22754210 Most congenital neutropenia is diagnosed because of fever and severe infection in infants and young children.
PubMedID- 23805898 fever during neutropenia is a frequent problem in patients with hematological malignancies and is the most common cause of non-malignant morbidity and mortality in this patient group 1.
PubMedID- 20351213 We conclude that brrna rt-qpcr could be useful in the diagnosis of fever with neutropenia, given its high bacterial detection rate, short turnaround time, and the small blood sample required compared with the standard blood culture techniques.
PubMedID- 24793316 Dengue fever as a cause of febrile neutropenia in adult acute lymphoblastic leukemia: a single center experience.
PubMedID- 22479278 Dlts were defined as grade 4 neutropenia associated with fever for more than 3 days; grade 4 neutropenia lasting for more than 10 days; grade 3-4 thrombocytopenia with grade 2 hemorrhage; or grade 3-4 non-hematologic toxicity during the first treatment cycle.
PubMedID- 21373895 Dose-limiting toxicity (dlt) during cycle 1 included: (1) neutrophil nadir < 500/mul attributed to therapy, (2) platelet nadir < 50,000/mul attributed to therapy, (3) grade 3-4 non-hematologic toxicity attributed to therapy, and (4) neutropenia associated with grade 2 fever (i.e., febrile neutropenia).
PubMedID- 21883896 Serum cea levels were even increased under everolimus 5 mg a day as compared to baseline and mildly decreased after increasing the dose to 10 mg. then, because of insurgence of grade 2 anaemia and grade 3 neutropenia with fever and need of antibiotic therapy, everolimus was discontinued until recovery to grade 1 haematological toxicity.
PubMedID- 23164244 The most common symptoms on presentation were fever with neutropenia, infection, pain, fever, and shortness of breath (n = 16 studies).
PubMedID- 23710669 The experience of use fq in fever with neutropenia or in critically ill children has been limited.
PubMedID- 22661287 Common terminology criteria of adverse events (ctcae) grade >/= 3 neutropenia (with or without fever) occurred in 34% of patients overall.
PubMedID- 21791058 A dlt was defined as treatment-related grade 3 fatigue for ≥ 7 days or grade 4 fatigue; grade 3 or 4 nausea/vomiting despite maximum supportive care; grade 3 neutropenia with fever > 38.5°c or grade 4 neutropenia; grade 4 thrombocytopenia for ≥ 7 days; grade 4 anemia; grade 4 hypertension; alanine aminotransferase or aspartate aminotransferase > 10 times the upper limit of normal; grade 3 rash for ≥ 7 days despite maximum supportive care or grade 4 rash; grade 3 diarrhea for ≥ 7 days despite maximum supportive care or grade 4 diarrhea; or any other treatment-related hematologic or nonhematologic grade 3 or 4 toxicity (except alopecia) occurring in the first 5 weeks of treatment.
PubMedID- 23098625 Haematological toxicity was the most common grade three or four toxicity and presented as thrombocytopenia, neutropenia with or without fever, anaemia or leukopenia.
PubMedID- 24434034 neutropenia with fever (febrile neutropenia fn) is a serious consequence of myelosuppressive chemotherapy that usually results in hospitalization and the need for intravenous antibiotics.
PubMedID- 21610706 Dose-limiting toxicity was defined as one of the following adverse events (aes) occurring during cycle 1: grade 4 haematological toxicity; grade 3 neutropenia with infection or fever ⩾38.5°c; grade ⩾3 non-haematological treatment-related toxicity, except toxicities which had not been maximally treated (such as nausea, vomiting and diarrhoea) or that the patient considered tolerable (such as skin rash); confirmed grade 3 qtc prolongation (qtc >500 ms) persisting after correction of other possible causes such as electrolyte imbalance or hypoxia; or inability to receive the next dose of pd 0332991 within 1 week (±1 day) of the last dose because of lack of haematological recovery or prolonged non-haematological toxicity grade ⩾3.
PubMedID- 23963141 None of the six patients entered at dose level 1 experienced dlt in cycle 1, allowing escalation to dose level 2. at dose level 2, one out of the six patients experienced dlt (fever with grade 4 neutropenia and grade 3 thrombocytopenia, leading to death) in cycle 1, allowing escalation to dose level 3. at dose level 3, the first (grade 4 thrombocytopenia) and the third (grade 3 hyperglycemia) patients experienced dlts during cycle 1; thus, level 2 was regarded as the highest well-tolerated dose and this cohort was expanded by an additional six patients to obtain additional safety and pharmacokinetic data.
PubMedID- 22395759 Purpose of review: fever in neutropenia is the most frequent potentially life-threatening complication of chemotherapy in children and adolescents with cancer.
PubMedID- 23293699 Grade 3 fatigue, dehydration, diarrhea, neutropenia with or without fever, lymphopenia, anemia, hyperbilirubinemia, and transaminitis occurred in >/=10% of the patients.
PubMedID- 21559248 Dose-limiting toxicity was defined as grade 3 fatigue persisting for ≥7 days or grade 4 fatigue; grade 3 or 4 nausea, diarrhea, or vomiting despite maximum supportive care; symptomatic pulmonary embolism (incidental asymptomatic pulmonary embolism or deep vein thrombosis identified during routine tumor imaging procedures was not dlts); grade 3 or 4 neutropenia with fever >38.5°c; grade 4 neutropenia (absolute neutrophil count <0.5 × 109/l) or thrombocytopenia (platelet count <25 × 109/l) for >7 days; grade 4 hypertension; grade 4 rash/desquamation; grade 4 hypertension; ast or alt >10 × uln; symptomatic hypomagnesemia despite intravenous magnesium replacement; any other motesanib- and/or panitumumab-related grade 4 hematologic or grade 3 nonhematologic toxicity that was unacceptable in duration during the dlt period (cycle 1).
PubMedID- 26524019 Methods: blood samples obtained from 76 fever patients with al during neutropenia episodes were detected to analyse single nucleotide polymorphism (snp) in the mbl exoni 54 and nfkappab1-94ins/del attg gene, and analyse the correlation between above-menthioned 2 polymorphisms and fever during neutropenia of al patients after chemotherapy.
PubMedID- 25955833 After she developed fever with neutropenia, she was admitted on day 1 for treatment with antibiotics as per protocol.
PubMedID- 22333598 For haematological toxicities, dlt was defined as a grade 4 neutropenia with fever, grade 4 neutropenia without fever for ⩾7 days, or grade 4 thrombocytopenia.
PubMedID- 26020806 neutropenia with or without fever was the predominant dlt for this sequence.
PubMedID- 19735276 Fifty-six episodes of persistent fever with neutropenia requiring eaft were recorded among 49 patients.
PubMedID- 21563549 Except for neutropenia with neutropenic fever and alopecia, no nci-ctc grade iii or iv toxicity was observed.
PubMedID- 20579327 neutropenia with fever occurred in 8% of dogs after treatment with vinblastine and in 2% after treatment with ccnu.
PubMedID- 25002906 After her induction chemotherapy the only presenting clinical sign was fever in the presence of severe neutropenia without an evident infectious focus.
PubMedID- 26421015 Adult filipino febrile neutropenia patients with prolonged fever >7 days prior to admission, known pathogen on cultures, and nadir anc < 100 during admission were at significant risk of developing worse outcomes, whereas those with g-csf use and complete antibiotic therapy were significantly associated with better outcomes.
PubMedID- 23989947 Dose-limiting toxicities (dlts) were evaluated during cycle 1 and were defined as follows: anc <0.5 × 109 per l for >5 days; grade 3 neutropenia with fever (⩾38.5 °c), sepsis or other severe infection; platelet count <25.0 × 109 per l; any other grade 3/4 nonhaematological adverse event (ae) suspected to be treatment related (except for nausea/vomiting without an optimal antiemetic regimen, hypersensitivity reactions and nonclinically relevant biochemical abnormalities); and any delays in the administration of a subsequent plitidepsin dose exceeding 2 weeks, or omissions of the infusions scheduled on days 8 and 15 because of treatment-related aes.
PubMedID- 25961061 The maximal tolerated dose (mtd) for daily iv infusions was 30 μg/kg, and dose-limiting toxicities consisted of hepatotoxicity, neutropenia, and lightheadedness with fever and rigors.
PubMedID- 20509945 Only patients that presented fever during neutropenia (defined as a neutrophil count <500 μl) were included in the second phase of the study.
PubMedID- 23423490 The dlts were defined as follows: (1) grade 4 hematological toxicity, (2) transfusion of platelets for thrombocytopenia, (3) grade 3 neutropenia with infection or fever >38.0 °c, (4) grade 3 or greater non-hematological toxicity with the exception of loss of appetite, nausea, and vomiting, and (5) treatment delay of more than 2 weeks following the last administration of docetaxel.
PubMedID- 23320053 fever during neutropenia is caused by an infection in more than 95% of cases, however in 50–70% of patients no infectious pathogen can be detected , , .
PubMedID- 20878160 One patient had grade 3 neutropenia lasting 5 days with fever, 1 had grade 3 anemia, 1 experienced grade 2 nausea, two experienced grade 2 anorexia, one had grade 1 mucositis, and one patient experienced grade 2 sensory neuropathy.
PubMedID- 22240796 A dlt was defined as any tak-285-related grade 4 haematological toxicity, grade 3 or worse non-haematological toxicity, grade 3 or worse neutropenia (<1000 mm–3) with fever of 38 °c or higher, or toxicity resulting in cessation of treatment for >21 consecutive days (including the stipulated period of observation without treatment).
PubMedID- 26543377 Irradiation was interrupted for grade ≥3 esophagitis, grade 3 neutropenia with fever, or grade 4 neutropenia.
PubMedID- 23164412 Ten to fifty percent of patients with solid tumors and 80% of those with hematologic malignancies will develop fever associated with neutropenia during more than one chemotherapy cycle .
PubMedID- 20564143 The dose-limiting toxicities (dlts) were fever with grade 3/4 neutropenia, grade 3 fatigue, and grade 3 mucositis.

Page: 1 2